{
    "eid": "2-s2.0-85133283782",
    "title": "Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening",
    "cover-date": "2022-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Kamonpan Sanachai",
        "Tuanjai Somboon",
        "Patcharin Wilasluck",
        "Peerapon Deetanya",
        "Peter Wolschann",
        "Thierry Langer",
        "Vannajan Sanghiran Lee",
        "Kittikhun Wangkanont",
        "Thanyada Rungrotmongkol",
        "Supot Hannongbua"
    ],
    "citedby-count": 5,
    "ref-count": 75,
    "ref-list": [
        "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
        "A Novel Coronavirus from Patients with Pneumonia in China, 2019",
        "Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)",
        "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",
        "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province",
        "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China",
        "Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment",
        "Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery",
        "Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography",
        "SARS-CoV-2 Main Protease: A Molecular Dynamics Study",
        "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors",
        "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors",
        "Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease",
        "Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease",
        "Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2",
        "Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease",
        "Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease",
        "Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19",
        "Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19",
        "Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19",
        "Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations",
        "Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332",
        "Structure-Based Virtual Screening: From Classical to Artificial Intelligence",
        "Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target",
        "Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic",
        "Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M(pro)",
        "Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors",
        "Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen",
        "Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing",
        "DrugBank 5.0: a major update to the DrugBank database for 2018",
        "A fast flexible docking method using an incremental construction algorithm",
        "UCSF chimera\u2014A visualization system for exploratory research and analysis",
        "ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB",
        "Development and testing of a general amber force field",
        "Particle Mesh Ewald\u2014an N.Log(N) Method for Ewald Sums in Large Systems",
        "Thermostat algorithms for molecular dynamics simulations",
        "LINCS: A linear constraint solver for molecular simulations",
        "Structural insight into the recognition of S-adenosylL-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2\u2019-O-Methyltransferase",
        "Rosmarinic Acid as a Potent Influenza Neuraminidase Inhibitor: In Vitro and In Silico Study",
        "Binding Hotspot and Activation Mechanism of Maltitol and Lactitol toward the Human Sweet Taste Receptor",
        "Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation",
        "PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data",
        "MMPBSA.py: An Efficient Program for End-State Free Energy Calculations",
        "Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space",
        "LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters",
        "KNIME-CDK: Workflowdriven cheminformatics",
        "Interaction of 8-anilinonaphthalene-1-sulfonate with SARS-CoV-2 main protease and its application as a fluorescent probe for inhibitor identification",
        "Production of authentic SARS-CoV M-pro with enhanced activity: Application as a novel tag-cleavage endopeptidase for protein overproduction",
        "Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction",
        "In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease",
        "Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease",
        "Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports",
        "Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline",
        "Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies",
        "Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study",
        "Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients",
        "Inhibition of SARS-CoV 3CL protease by flavonoids",
        "Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target",
        "Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation",
        "In silico prediction of human sulfotransferase 1E1 activity guided by pharmacophores from molecular dynamics simulations",
        "Pharmacoinformatics elucidation of potential drug targets against migraine to target ion channel protein KCNK18",
        "An investigation of antidiabetic activities of bioactive compounds in Euphorbiahirta Linn using molecular docking and pharmacophore",
        "Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anticancer agents targeting XIAP protein",
        "Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies",
        "Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations",
        "Pharmacophore modeling and applications in drug discovery: challenges and recent advances",
        "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules",
        "Lead- and drug-like compounds: the rule-of-five revolution",
        "A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases",
        "DrugBank: a comprehensive resource for in silico drug discovery and exploration",
        "Molecular properties that influence the oral bioavailability of drug candidates",
        "Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Vienna",
            "@id": "60025988",
            "affilname": "Universit\u00e4t Wien",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025988",
            "affiliation-country": "Austria"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60029157",
            "affilname": "Universiti Malaya",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029157",
            "affiliation-country": "Malaysia"
        }
    ],
    "funding": []
}